NCT06106802 2026-02-23
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Samsung Medical Center
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06268210 2026-02-09
NeoLazer
Yonsei University
Phase 2 Recruiting
NCT05786430 2026-01-27
LUCAS
Yonsei University
Phase 2 Active not recruiting
NCT04965090 2025-12-18
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05299125 2025-10-01
AMIGO-1
Latin American Cooperative Oncology Group
Phase 2 Active not recruiting